Blood-based biomarkers have transformed Alzheimer’s disease (AD) diagnostics, offering minimally invasive and cost-effective solutions. However, traditional AD blood testing presents logistical challenges, including the need for venous blood draws, specialized lab infrastructure, and temperature-controlled transport. 

Discover how Simoa® ultra-sensitive detection enables dried blood spot (DBS) and dried plasma spot (DPS) biomarker testing—revolutionizing Alzheimer’s research and clinical applications. 

Key Highlights: 

• Breakthrough in Remote Sample Collection: Finger-prick DBS and DPS testing eliminate the need for venous blood draws and cold storage. 

• Proven Performance in AD Biomarker Detection: Studies demonstrate a strong correlation between DBS/DPS biomarker levels and standard plasma samples. 

• Advancing At-Home Testing: Early data suggests self-administered DPS collection could enable widespread monitoring. 

• Expanding Beyond Alzheimer’s: Potential applications include neurological conditions such as multiple sclerosis and traumatic brain injury.